The AUC for somatostatin receptor PET imaging addresses a number of medical situations for diagnosing neuroendocrine tumors (NETs). To develop these criteria, SNMMI labored collaboratively with the European Association of Nuclear Medicine (EANM), the European Neuroendocrine Tumor Society (ENETS), the American Gastroenterological Association (AGA), the American Society of Clinical Oncology (ASCO), the American College of Radiology (ACR), the National Comprehensive Cancer Network (NCCN), the American Joint Committee on Cancer (AJCC), the North American Neuroendocrine Tumor Society (NANETS), the National Cancer Institute (NCI), the Endocrine Society, the American Association of Engineering Societies (AAES), and the Society of Surgical Oncology (SSO).
SNMMI assembled an autonomous Somatostatin Receptor PET Imaging in Neuroendocrine Tumors Workgroup consisting of specialists within the area of nuclear medicine together with radiologists, pharmacologists, endocrinologists, surgeons and oncologists to evaluate the scientific literature and develop consensus suggestions for the medical use of this know-how. The Oregon Health Science University’s (OHSU) Evidence-based Practice Center (EPC) carried out a scientific evaluate of present proof based mostly on the scope and parameters that the workgroup put collectively, which have been then used to make the suggestions for medical use.
The SNMMI Guidance Oversight Committee can also be creating AUC for gastrointestinal transit, an infection imaging, PET myocardial perfusion imaging, prostate most cancers imaging, somatostatin imaging, and thyroid imaging and remedy.